Okupe Oluyemi, Chief Financial Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), exercised stock options and subsequently sold shares of the company’s Class A Common Stock on July 6, 2026. These transactions were executed pursuant to a Rule 10b5-1 trading plan that Mr. Okupe adopted on May 21, 2025.

Mr. Okupe sold 7,163 shares of Class A Common Stock for a total value of approximately $261,351. The shares were sold at an average weighted price of $36.4863 per share, with individual sales occurring within a price range of $36.35 to $36.70.The transaction comes as the stock has gained over 10% in the past week, though InvestingPro analysis suggests the company is currently overvalued relative to its Fair Value. With a market cap of $8.4 billion and revenue growth of 33%, the telehealth company maintains a "GREAT" financial health score. For deeper insights, investors can access the comprehensive Pro Research Report, available for HIMS and 1,400+ other US equities.

Prior to the sale, Mr. Okupe acquired 7,163 shares of Class A Common Stock by exercising stock options at a price of $5.01 per share, totaling approximately $35,886. These options were part of a grant where 25% vested on the twelve-month anniversary of January 24, 2022, with the remaining balance vesting in monthly installments thereafter, contingent on continuous service. The exercised options had an expiration date of February 23, 2032.

Following these transactions, Mr. Okupe directly holds 284,321 shares of Hims & Hers Health, Inc. Class A Common Stock. Additionally, 7,853 shares are held indirectly by the Oluyemi Okupe Separate Property Trust.

In other recent news, Hims and Hers Health has seen a series of positive developments. The company received a price target increase from Barclays, which raised it to $39 from $29, maintaining an Overweight rating. This decision was influenced by data showing improved performance following a partnership with Novo Nordisk, as website traffic saw significant year-over-year increases in April and May. Canaccord also raised its price target for Hims and Hers to $40 from $32, maintaining a Buy rating, citing the company’s transition from compounded to branded weight loss drugs and its strong partnership with Novo Nordisk.

Additionally, BofA Securities adjusted its price target to $36 from $25, while keeping a Neutral rating, noting the impact of the FDA’s review of wellness peptides. The FDA’s move to review and potentially remove certain peptides from the restricted list could open up a new market for the company. These analyst updates reflect a positive outlook on Hims and Hers Health’s recent strategic moves and market opportunities. The company’s efforts in the weight loss drug sector and its partnerships have been highlighted as key factors in these assessments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.